Compounded Injectable Tirzepatide: The Dual GIP/GLP-1 Protocol and What the Data Shows
When the SURMOUNT-1 trial results were published in the New England Journal of Medicine in 2022, the obesity medicine community took notice: tirzepatide 15mg produced a mean weight reduction of 22.5% over 72 weeks — a number that was previously the exclusive domain of bariatric surgery.
Tirzepatide's unique mechanism — dual agonism of both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors — may explain why it consistently outperforms single-action GLP-1 agonists in head-to-head and parallel trials.
The Dual Mechanism Explained
**GLP-1 receptor agonism:** As with semaglutide, tirzepatide activates GLP-1 receptors in the hypothalamus (appetite suppression), GI tract (delayed gastric emptying), and pancreas (insulin stimulation, glucagon suppression).
**GIP receptor agonism:** GIP (glucose-dependent insulinotropic polypeptide) is the other primary incretin hormone. GIP receptor activation has distinct effects from GLP-1:
In adipose tissue, GIP receptors modulate fat storage and mobilization — potentially contributing to tirzepatide's superior fat mass reduction
GIP appears to improve GLP-1 receptor sensitivity — meaning co-activation of GIP receptors may amplify GLP-1 signaling pathways
GIP has direct effects on satiety centers in the brain, independent of GLP-1 pathways
The combined effect produces appetite suppression, metabolic improvement, and fat mass reduction that consistently exceeds single-action GLP-1 therapy.
What the SURMOUNT Trials Found
SURMOUNT-1: (72 weeks, n=2,539): Tirzepatide 15mg → 22.5% body weight reduction; 5mg → 15.0%; 10mg → 19.5%
SURMOUNT-2: (72 weeks, type 2 diabetes population): Tirzepatide 15mg → 15.7% body weight reduction, with HbA1c reductions of 2.5% from baseline
SURMOUNT-4: (weight maintenance): 21.1% weight reduction maintained at 88 weeks in patients continuing tirzepatide
Compounded vs. Brand-Name Tirzepatide
Compounded tirzepatide — prepared at licensed compounding pharmacies with B12 as the primary additive — is not FDA-approved as a standalone formulation and is not the same as the FDA-approved branded versions. The active molecule is tirzepatide, but compounded formulations have not undergone FDA safety and efficacy review as individual products.
Patients receive medication, syringes, and all supplies for self-administration. Dose changes at physician direction are included at no additional cost.
Compounded injectable tirzepatide is a prescription medication. Not everyone qualifies. A licensed provider determines eligibility based on medical history and BMI.
